HALOZYME THERAPEUTICS ($HALO) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $1.11 per share, beating estimates of $0.96 by $0.15. The company also reported revenue of $264,860,000, beating estimates of $234,781,560 by $30,078,440.
You can see Quiver Quantitative's $HALO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HALOZYME THERAPEUTICS Insider Trading Activity
HALOZYME THERAPEUTICS insiders have traded $HALO stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- JEFFREY WILLIAM HENDERSON has made 0 purchases and 8 sales selling 25,000 shares for an estimated $1,378,719.
- MICHAEL J. LABARRE (SVP, CHIEF TECHNICAL OFFICER) has made 0 purchases and 6 sales selling 21,697 shares for an estimated $1,260,680.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HALOZYME THERAPEUTICS Hedge Fund Activity
We have seen 277 institutional investors add shares of HALOZYME THERAPEUTICS stock to their portfolio, and 252 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 1,760,323 shares (-56.2%) from their portfolio in Q4 2024, for an estimated $84,161,042
- BANK OF AMERICA CORP /DE/ added 1,378,955 shares (+66.6%) to their portfolio in Q4 2024, for an estimated $65,927,838
- FRONTIER CAPITAL MANAGEMENT CO LLC removed 1,269,827 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $60,710,428
- CITADEL ADVISORS LLC added 1,262,757 shares (+inf%) to their portfolio in Q4 2024, for an estimated $60,372,412
- CIBC PRIVATE WEALTH GROUP LLC removed 963,451 shares (-99.7%) from their portfolio in Q4 2024, for an estimated $46,062,592
- CAPITAL WORLD INVESTORS added 748,230 shares (+inf%) to their portfolio in Q4 2024, for an estimated $35,772,876
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 636,589 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $30,435,320
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HALOZYME THERAPEUTICS Congressional Stock Trading
Members of Congress have traded $HALO stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $HALO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 03/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
HALOZYME THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $HALO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 01/10/2025
To track analyst ratings and price targets for HALOZYME THERAPEUTICS, check out Quiver Quantitative's $HALO forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
